Skip to content
10-Q

Quarterly Report

MEREO BIOPHARMA GROUP PLC MREO

0000950170-25-069816

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 795M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $62.48M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $69.8M
Current Liabilities Q1 2025 · Mar 31, 2025 $7.5M
Current Liabilities Q1 2025 · Dec 31, 2024 $13.85M
Total Liabilities Q1 2025 · Mar 31, 2025 $8.24M
Total Liabilities Q1 2025 · Dec 31, 2024 $15.42M
Current Assets Q1 2025 · Mar 31, 2025 $66.9M
Current Assets Q1 2025 · Dec 31, 2024 $74.76M
Total Assets Q1 2025 · Mar 31, 2025 $68.32M
Total Assets Q1 2025 · Dec 31, 2024 $76.39M
Stock Issued Q1 2025 · Feb 28, 2025 17.11M sh
Shares Diluted Q1 2025 · Mar 31, 2024 700.26M sh
Capex Q1 2025 · Mar 31, 2024 $0
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$7.99M
Stockholders Equity Q1 2025 · Mar 31, 2024 $42.84M
Stockholders Equity Q1 2025 · Dec 31, 2023 $50.54M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.01
Eps Basic Q1 2025 · Mar 31, 2024 −$0.01
Sga Expense Q1 2025 · Mar 31, 2024 $5.91M
Rd Expense Q1 2025 · Mar 31, 2024 $3.99M
Net Income Q1 2025 · Mar 31, 2024 −$8.95M
Operating Income Q1 2025 · Mar 31, 2024 −$9.9M